The Drug Regulatory Authority of Pakistan (DRAP) has formally requested the Pakistan Telecommunication Authority (PTA) to block websites and online platforms involved in the sale of unauthorized and unregistered therapeutic goods.
In a statement, DRAP said the action targets several websites and social media pages promoting unapproved medicines, particularly products claiming to treat sexual health issues, weight loss, and mental disorders. The regulator warned that the growing online availability of such products poses a serious threat to public health.
Concerns over smuggled and unapproved drugs
According to DRAP, some of the medicines being sold online are suspected to be smuggled from neighboring countries, including India and Iran. These drugs are often marketed without medical prescriptions, in clear violation of the Drugs Act, 1976.
The authority stressed that unregistered and smuggled medicines are not evaluated for safety, quality, or efficacy, making them potentially dangerous for consumers.
Platforms identified for illegal sales
DRAP said it has identified specific online platforms allegedly involved in the illegal trade of medicines, including:
- herbaltelestore.pk
- opentelstore.com
- curepill.pk
- radiance360.shop
The regulator has also called for the immediate removal of related advertisements from social media platforms, warning that companies failing to comply could face legal consequences.
Public health risks highlighted
DRAP cautioned that unapproved medicines may cause severe side effects, long-term health complications, and in some cases, fatal outcomes. Officials added that aggressive online marketing increases the risk of misuse, especially among vulnerable consumers seeking quick or discreet treatments.
Enforcement action and public advisory
The authority announced strict enforcement measures, including heavy fines, seizure of illegal products, and legal action against individuals and entities involved in the sale and promotion of unauthorized medicines.
DRAP also urged the public to avoid purchasing medicines from unverified online sources and to report suspicious activities. It reiterated that all drug-related advertisements must receive prior approval to prevent the spread of misleading or harmful health information.
